| Savient Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript Savient Pharmaceuticals, Inc. (SVNT)Q1 2010 Earnings Call TranscriptMay 6, 2010 10:00 am ETComplete Story » seekingalpha.com |
8 Healthcare Sector Takeover Targets Kapitall submits:According to reports, French pharma giant Sanofi-Aventis (SNY) is considering making several U.S. biotech acquisitions; including one or two that could be worth at least $15 billion.On the news shares of Biogen (BIIB), Allergan (AGN) and Genzyme (GENZ) all shot higher.Complete Story » seekingalpha.com |
Seattle Genetics, Inc. Q2 2010 Earnings Call Transcript Seattle Genetics, Inc. (SGEN)Q2 2010 Earnings CallJuly 27, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Alexza's Staccato: Setting Up as a New Platform for 'Inhalation Technology' Sheff Station submits:The Staccato technology and loxapine that make up AZ-004 will be on display on October 11th as Alexza (ALXA) looks for approval from the FDA. My previous article focused on how Alexza was clearing hurdles to move into a strong position with the FDA. What this article will do is discuss the history of the Staccato technology and its applicability and use in drug delivery with specific emphasis on AZ-004.Alexza and the Staccato technology was founded by Dr. Alex Zaffaroni. The company was built on the concept of the Staccato technology in use for treating acute and intermittent conditions. Alexza has developed a deep pipeline of products in a short period of time as they have put 5 products into the clinic in only 4 years. Capital constraints have caused Alexza to focus on AZ-004 in 2010. They have (pdf) 2 migraine programs, a pain program, AZ-002 Staccato alprazolane which they studied in panic, and AZ-007 which is part of their sleep program.Complete Story » seekingalpha.com |
Immunogen, Exelixis: Right Deals at the Right Time Ohad Hammer submits:Yesterday, both Immunogen (IMGN) and Exelixis (EXEL) announced two important partnership deals. As with any deal, both companies enjoy an injection of non-dilutive funds as well as a vote of confidence for the companies’ technologies. This time, however, it seems the deals, which could not have come in a better time, represent much more than that. Immunogen announced a broad licensing deal with Novartis (NVS) which provides the pharma giant with rights to use Immunogen’s antibody drug conjugate (ADC) technology for an undisclosed number of targets. The numbers demonstrate the huge appreciation in the value of Immunogen’s technology compared to several years ago. The deal includes an upfront payment of $45M as well as $200M in milestone payments for every program Novartis chooses to develop. For the sake of comparison, current agreements with Genentech and Sanofi Aventis (SNY) entail milestone payments of in the $20-40 million range.Complete Story » seekingalpha.com |